Director, Health Economics & Outcomes Research

Alcon Research•Fort Worth, TX

19h•Onsite

About The Position

The Director, Health Economics & Outcomes Research – Pharma serves as a strategic HEOR leader for Alcon’s pharmaceutical portfolio. The role translates clinical, economic, real-world, and patient-centered evidence into actionable strategies that support product development, value demonstration, reimbursement, and patient access. It leads evidence strategies for priority pharmaceutical assets to support future market access, reimbursement, value communication, and successful product launches in the U.S. and globally. This is an on-site position in Fort Worth, Texas, with travel of up to 20%. Relocation is available; sponsorship is not available. The Director also contributes to developing the Pharma HEOR function, including its research standards, governance, prioritization processes, operating models, and scalable capabilities.

Requirements

Bachelor’s degree or equivalent years of directly related experience; alternatives listed are high school plus 18 years, associate degree plus 14 years, M.S. plus 7 years, or Ph.D. plus 6 years.
Fluency in reading, writing, understanding, and communicating in English.
10 years of relevant experience.
6 years of demonstrated leadership.

Nice To Haves

PhD, PharmD, MPH, MS, or equivalent advanced degree in health economics, outcomes research, epidemiology, public health, pharmacy, or a related field.
Experience supporting pharmaceutical product launches.
Experience with U.S. payer evidence requirements and global HTA processes.
Experience with global value dossiers, AMCP dossiers, economic models, and value communication tools.
Experience managing HEOR vendors and external research collaborations.
Experience supporting specialty, biologic, or advanced-therapy products.

Responsibilities

Develop and execute integrated HEOR and evidence-generation strategies aligned with asset development plans, target product profiles, regulatory strategy, global market access priorities, and commercialization objectives.
Lead HEOR contributions to launch preparation, including payer evidence planning, value proposition development, evidence dissemination strategies, reimbursement support tools, and cross-functional launch readiness activities.
Represent HEOR on cross-functional asset teams and influence clinical development plans, endpoint strategies, evidence requirements, stage-gate decisions, and launch-readiness planning.
Identify evidence gaps and translate payer, health technology assessment, provider, and patient needs into prioritized research plans, including evidence synthesis, burden-of-disease studies, real-world evidence, patient-reported outcomes, comparative effectiveness research, and economic modeling.
Lead development of global value evidence and communication resources, including value dossiers, economic models, payer evidence materials, publications, and other tools supporting reimbursement and access decisions.
Anticipate U.S. payer and ex-U.S. HTA evidence requirements and partner with regional and country teams to adapt global strategies to local reimbursement needs.
Provide HEOR input into early asset assessments, business development and licensing opportunities, product differentiation, value proposition development, and pricing and reimbursement strategy.
Ensure HEOR projects are scientifically rigorous, compliant with applicable standards and procedures, delivered within approved budgets and timelines, and effectively communicated to technical and nontechnical stakeholders.
Manage external research partners, including project scoping, vendor selection, contracting, budget oversight, quality review, and delivery of high-impact evidence.
Build organizational understanding of HEOR and strengthen cross-functional capabilities by communicating the strategic and business implications of evidence to senior leaders and key partners.
Contribute to the continued development of the Pharma HEOR function, including research standards, governance, prioritization processes, operating models, and scalable capabilities.